

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN	TORALIZUMAB
PRONUNCIATION	toe ra lye' zyoo mab
THERAPEUTIC CLAIMS	treatment of antibody-mediated disorders (immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantation such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and B-cell malignancies such as CLL/small lymphocytic lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenstrom's macroglobulinemia, monocytoid B-cell lymphoma; relapsed/refractory Hodgkin's disease) (monoclonal antibody)
CHEMICAL NAME	
	1) immunoglobulin G1, anti-(human CD40 ligand) (human-mouse monoclonal IDEC-131 γ 1 chain), disulfide with human-mouse monoclonal IDEC-131 κ -chain, dimer
MOLECULAR WEIGHT	Approximately 148,426 Daltons
TRADEMARK	Unknown as yet
MANUFACTURER	IDEC Pharmaceuticals Corporation
CODE DESIGNATIONS	anti-gp39; anti-CD40L; anti-CD154
<u>CAS</u> REGISTRY NUMBER	252662-47-8